Lonza news

The new cGMP line in Visp is operational, with first batches in April 2023. It supports clinical and commercial needs, enhancing end-to-end solutions and complementing recent site expansions.

The expansion includes two new manufacturing suites, enhancing capabilities for clinical and commercial supply, and increasing process, analytical development, and quality control capacity.

The CHF 500M facility, set for 2026 completion, will enhance end-to-end drug product manufacturing, leveraging existing infrastructure and focusing on sustainability with a photovoltaic roof.

Investment in new filling line and expanded Drug Product Services in Stein and Basel will enhance capabilities for various drug modalities, creating over 70 jobs and supporting clinical and commercial stages.